Accretion Nutraveda Ltd
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms.[1]
- Market Cap ₹ 227 Cr.
- Current Price ₹ 313
- High / Low ₹ 313 / 150
- Stock P/E 44.7
- Book Value ₹ 49.0
- Dividend Yield 0.00 %
- ROCE 27.7 %
- ROE 25.0 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 35.0%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 60.3 to 88.1 days.
- Working capital days have increased from 111 days to 196 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 2.89 | 5.01 | 16.00 | 33.59 | |
| 2.27 | 3.78 | 12.29 | 26.70 | |
| Operating Profit | 0.62 | 1.23 | 3.71 | 6.89 |
| OPM % | 21.45% | 24.55% | 23.19% | 20.51% |
| 0.17 | 0.19 | 0.01 | 0.11 | |
| Interest | 0.19 | 0.24 | 0.35 | 0.53 |
| Depreciation | 0.31 | 0.26 | 0.22 | 0.26 |
| Profit before tax | 0.29 | 0.92 | 3.15 | 6.21 |
| Tax % | 3.45% | 9.78% | 20.63% | 18.36% |
| 0.28 | 0.82 | 2.50 | 5.07 | |
| EPS in Rs | 7.78 | 22.78 | 51.33 | 7.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 127% |
| TTM: | 110% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 163% |
| TTM: | 103% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 35% |
| Last Year: | 25% |
Balance Sheet
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.36 | 0.36 | 0.49 | 7.24 |
| Reserves | -0.10 | 0.72 | 4.56 | 28.23 |
| 1.97 | 2.17 | 3.86 | 4.23 | |
| 1.83 | 1.39 | 1.63 | 2.08 | |
| Total Liabilities | 4.06 | 4.64 | 10.54 | 41.78 |
| 1.49 | 1.28 | 1.83 | 1.66 | |
| CWIP | 0.00 | 0.10 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| 2.57 | 3.26 | 8.71 | 40.12 | |
| Total Assets | 4.06 | 4.64 | 10.54 | 41.78 |
Cash Flows
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 0.68 | 0.23 | -2.22 | -9.42 | |
| -0.01 | -0.16 | -0.87 | -14.50 | |
| -0.63 | -0.04 | 2.98 | 25.19 | |
| Net Cash Flow | 0.04 | 0.03 | -0.10 | 1.26 |
| Free Cash Flow | 0.67 | 0.07 | -3.09 | -15.45 |
| CFO/OP | 110% | 27% | -42% | -113% |
Ratios
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 101.04 | 18.21 | 74.60 | 88.13 |
| Inventory Days | 279.12 | 303.74 | 158.50 | 136.10 |
| Days Payable | 354.26 | 113.58 | 30.73 | 11.35 |
| Cash Conversion Cycle | 25.89 | 208.37 | 202.36 | 212.87 |
| Working Capital Days | 8.84 | 7.29 | 128.89 | 195.59 |
| ROCE % | 42.34% | 57.57% | 27.73% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Capacity Utilization - Capsule % |
|
||
| Capacity Utilization - Tablet % |
|||
| Customer Concentration - Top 5 Customers % of Total Sales |
|||
| Geographic Concentration - Gujarat % of Total Sales |
|||
| Production Volume - Capsule Numbers |
|||
| Production Volume - Tablet Numbers |
|||
Extracted by Screener AI
Documents
Announcements
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 (''Listing Regulations'')
- 5th AGM scheduled for 27 August 2026; annual report FY2025-26 sent to shareholders.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Advertisement of 05th Annual General Meeting and E-voting procedure.
- Reg. 34 (1) Annual Report.
- Notice Of The 5Th AGM Of The Company
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Advertisement of intimation of 05th Annual General Meeting of the Company through VC/OAVM.
Business Profile[1]
Accretion Nutraveda Limited is a healthcare-focused Ayurveda and Nutraceutical CDMO, manufacturing a wide range of Ayurvedic and nutraceutical products across multiple dosage forms for domestic clients, merchant exporters, and direct export customers.